Oct 19, 2026 08:00AM
Oct 19, 2026 08:00AM
Aug 12, 2026 07:30AM
Aug 3, 2026 08:01AM
Aug 3, 2026 08:00AM
Jul 29, 2026 06:53AM
Jul 28, 2026 07:00AM Altimmune's pemvidutide cuts heavy drinking days in phase 2 trial
Jul 28, 2026 07:00AM
May 28, 2026 11:00AM
May 28, 2026 11:00AM
May 27, 2026 08:01AM
May 27, 2026 08:00AM
May 19, 2026 06:48AM
May 13, 2026 08:30AM Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities
May 13, 2026 07:30AM
May 13, 2026 07:15AM
Mar 27, 2026 10:53AM
Mar 17, 2026 06:46AM
Mar 5, 2026 11:31AM
Mar 5, 2026 07:00AM
Jan 29, 2026 05:54PM Altimmune closes $75 million stock offering for liver drug trials
Jan 29, 2026 05:54PM
Jan 27, 2026 09:25PM
Jan 27, 2026 09:25PM
Jan 27, 2026 06:32AM
Jan 5, 2026 07:31AM
Jan 5, 2026 07:30AM
Dec 19, 2025 06:30AM Altimmune reports positive 48-week data for MASH drug pemvidutide
Dec 19, 2025 06:30AM
Dec 1, 2025 07:31AM
Dec 1, 2025 07:30AM
Nov 12, 2025 04:47AM
Nov 11, 2025 08:52AM
Nov 11, 2025 08:51AM
Nov 7, 2025 08:06AM Altimmune presents AI analysis showing liver fibrosis reduction with pemvidutide
Nov 7, 2025 08:05AM
Nov 6, 2025 07:00AM
Nov 3, 2025 07:30AM
Nov 3, 2025 07:30AM
Oct 20, 2025 07:30AM
Sep 29, 2025 07:30AM
Sep 29, 2025 07:30AM Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide 
Aug 19, 2025 07:30AM
Aug 19, 2025 07:30AM
Aug 12, 2025 07:00AM
Aug 11, 2025 07:30AM
Aug 11, 2025 07:30AM
Jul 9, 2025 07:30AM
Jul 9, 2025 07:30AM Altimmune Announces Initiation of RESTORE Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease (ALD)
Jun 26, 2025 07:02AM

334,859 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All